TrialOrphanet journal of rare diseases2014

An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.

Shahram Attarian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.